| Literature DB >> 25622724 |
Xin Zhang1,2, Wei Xuan3,4, Ping Yin5, Linlin Wang6,7, Xiaodan Wu8,9, Qingping Wu10,11.
Abstract
INTRODUCTION: The value of gastric intramucosal pH (pHi) can be calculated from the tonometrically measured partial pressure of carbon dioxide ([Formula: see text]) in the stomach and the arterial bicarbonate content. Low pHi and increase of the difference between gastric mucosal and arterial [Formula: see text] ([Formula: see text] gap) reflect splanchnic hypoperfusion and are good indicators of poor prognosis. Some randomized controlled trials (RCTs) were performed based on the theory that normalizing the low pHi or [Formula: see text] gap could improve the outcomes of critical care patients. However, the conclusions of these RCTs were divergent. Therefore, we performed a systematic review and meta-analysis to assess the effects of this goal directed therapy on patient outcome in Intensive Care Units (ICUs).Entities:
Mesh:
Year: 2015 PMID: 25622724 PMCID: PMC4350856 DOI: 10.1186/s13054-015-0739-6
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Baseline characteristics of included randomized controlled trials
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Gutierrez and colleagues [ |
|
|
|
| All patients received histamine-receptor-blocking agents throughout their ICU stay. |
| ICU survival, hospital survival |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
| Ivatury and colleagues [ |
|
|
|
| All patients in both groups received a low-dose dopamine (2 to 5 μg/kg/minute) infusion as a renal vasodilator. A histamine H2-receptor antagonist (cimetidine) was administered routinely to all the patients. |
| Overall survival |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
| Pargger and colleagues [ |
|
|
|
| Starting on the day of surgery, each patient was given 40 mg omeprazole intravenously at 24-hour intervals. |
| Hospital mortality, days on SICU, total days in hospital, days intubated. |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
| Gomersall and colleagues [ |
|
|
|
| Specific therapy to treat the patients’ underlying disease and other forms of organ dysfunction were prescribed as indicated clinically according to standard ICU treatment protocols. |
| ICU and hospital mortality, duration of ICU stay, duration of hospital stay. |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
| Hameed and colleagues [ |
|
|
|
| Immediately after randomization, subjects received 600 mg cimetidine intravenously. An additional 600 mg were administered every 12 hours. |
| Ventilator days, ICU length of stay, hospital length of stay, mortality. |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
| Palizas and colleagues [ |
|
|
|
| All patients received histamine H2-receptor antagonists, and enteral feeding was avoided throughout the study period. |
| Twenty-eight-day mortality, ICU length of stay. |
|
|
| ||||||
|
| |||||||
|
| |||||||
|
|
ACCP/SCCM, American College of Chest Physicians/ Society of Critical Care Medicine; APACHE, Acute Physiology and Chronic Health Evaluation; CI, cardiac index; pHi, intramucosal pH; SD, standard deviation; SICU, Surgical Intensive Care Unit; TICU, Trauma Intensive Care Unit.
Summary of risk of bias of included trials
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Gutierrez and colleagues [ | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk |
| Ivatury and colleagues [ | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk |
| Pargger and colleagues [ | Unclear risk | Unclear risk | Low risk | Low risk | Low risk | Unclear risk |
| Gomersall and colleagues [ | Low risk | Low risk | Unclear risk | Low risk | Low risk | Unclear risk |
| Hameed and colleagues [ | Low risk | Low risk | Unclear risk | Low risk | Low risk | Unclear risk |
| Palizas and colleagues [ | Unclear risk | Unclear risk | Low risk | Low risk | Low risk | Unclear risk |
pHi, intramucosal pH.
Figure 1Flow chart of study selection. RCT, randomized controlled trial.
Figure 2Effects of gastric tonometry guided therapy versus control groups on hospital mortality. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 3Effects of gastric tonometry guided therapy versus control groups on total mortality. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 4Effects of gastric tonometry guided therapy versus control groups on total mortality using risk difference. CI, confidence interval; RD, risk difference; W, weight of each study.
Figure 5Sensitivity analysis of total mortality. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 6Effects of gastric tonometry guided therapy versus control groups on ICU mortality. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 7Effects of gastric tonometry guided therapy versus control groups on ICU length of stay. CI, confidence interval; SD, standard deviation; SMD, standardized mean difference; W, weight of each study.
Figure 8Effects of gastric tonometry guided therapy versus control groups on hospital length of stay. CI, confidence interval; SD, standard deviation; SMD, standardized mean difference; W, weight of each study.
Figure 9Effects of gastric tonometry guided therapy versus control groups on number of days intubated. CI, confidence interval; SD, standard deviation; SMD, standardized mean difference; W, weight of each study.
Figure 10Subgroup analysis of ICU mortality for patients with normal admission gastric intramucosal pH. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 11Subgroup analysis of hospital mortality for patients with normal admission gastric intramucosal pH. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 12Subgroup analysis of ICU mortality for patients without normal admission gastric intramucosal pH. CI, confidence interval; OR, odds ratio; W, weight of each study.
Figure 13Subgroup analysis of hospital mortality for patients without normal admission gastric intramucosal pH. CI, confidence interval; OR, odds ratio; W, weight of each study.